According to a recent LinkedIn post from Truveta, new analysis from Truveta Research suggests that estrogen-based hormone replacement therapy prescribing has more than doubled between 2018 and 2026, with especially strong growth in patches and creams. The post notes that among women ages 45–54, use increased by 184%, reaching nearly 1 in 20 receiving a prescription by early 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post indicates these trends may reflect broader shifts in menopause care, influenced by evolving clinical evidence, higher patient awareness, and recent FDA actions. It also points to a move away from oral therapies and underscores how access to real-world data could be valuable in tracking adoption patterns, which may enhance Truveta’s positioning as a data and analytics provider to life sciences and healthcare stakeholders.